These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26727301)

  • 41. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study.
    Palau P; Mollar A; Domínguez E; Sanchis J; Bayés-Genís A; Núñez J
    Rev Esp Cardiol (Engl Ed); 2019 Feb; 72(2):167-169. PubMed ID: 29373254
    [No Abstract]   [Full Text] [Related]  

  • 44. Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Owens AT; Brozena S; Jessup M
    Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
    Renew JR; Cyrille N; Elyahu AY; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1500-1506. PubMed ID: 29373183
    [No Abstract]   [Full Text] [Related]  

  • 46. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Pham AQ; Patel Y; Gallagher B
    J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Orsborne C; Chaggar PS; Shaw SM; Williams SG
    Postgrad Med J; 2017 Jan; 93(1095):29-37. PubMed ID: 27671772
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    DeFilippis EM; Butler J; Vaduganathan M
    Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29138249
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic congestive heart failure - a new therapeutic choice.
    Parker JD; Ross HJ
    CMAJ; 2016 Nov; 188(16):1137-1138. PubMed ID: 27455977
    [No Abstract]   [Full Text] [Related]  

  • 52. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A new medication - when should one switch?].
    Fath R
    MMW Fortschr Med; 2016 May; 158(9):66. PubMed ID: 27155715
    [No Abstract]   [Full Text] [Related]  

  • 54. Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
    Bartell N; Frishman WH
    Cardiol Rev; 2017; 25(6):315-320. PubMed ID: 28984670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
    Docherty KF; McMurray JJV
    Cardiovasc Res; 2019 Nov; 115(13):e136-e139. PubMed ID: 31497841
    [No Abstract]   [Full Text] [Related]  

  • 56. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society.
    Straburzyńska-Migaj E; Nessler J; Gruchała M; Kamiński K; Lelonek M; Leszek P; Mizia-Stec K; Rozentryt P; Gackowski A; Gwizdała A; Jankowska EA; Ponikowski P
    Kardiol Pol; 2017; 75(3):286-293. PubMed ID: 28326531
    [No Abstract]   [Full Text] [Related]  

  • 58. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
    ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
    Hsiao R; Greenberg B
    Curr Heart Fail Rep; 2016 Aug; 13(4):172-80. PubMed ID: 27271564
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Ahn R; Prasad V
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):633-635. PubMed ID: 30232657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.